Cardiff Oncology, Inc.
CRDF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 40% | 26.4% | 7.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $37 | $33 | $27 | $17 |
| G&A Expenses | $12 | $13 | $13 | $12 |
| SG&A Expenses | $12 | $13 | $13 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $49 | $46 | $40 | $29 |
| Operating Income | -$49 | -$45 | -$40 | -$29 |
| % Margin | -7,123.1% | -9,305.7% | -10,337.3% | -8,037.6% |
| Other Income/Exp. Net | $3 | $4 | $1 | $1 |
| Pre-Tax Income | -$45 | -$41 | -$39 | -$28 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$45 | -$41 | -$39 | -$28 |
| % Margin | -6,651.7% | -8,492% | -10,026.9% | -7,880.5% |
| EPS | -0.95 | -0.93 | -0.89 | -0.73 |
| % Growth | -2.2% | -4.5% | -21.9% | – |
| EPS Diluted | -0.95 | -0.93 | -0.89 | -0.73 |
| Weighted Avg Shares Out | 48 | 45 | 44 | 39 |
| Weighted Avg Shares Out Dil | 48 | 45 | 44 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $4 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$48 | -$45 | -$40 | -$28 |
| % Margin | -7,064% | -9,224.2% | -10,276.2% | -7,912% |